MARKET

ACIU

ACIU

AC Immune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.39
-0.35
-4.52%
Closed 16:00 06/01 EDT
OPEN
7.60
PREV CLOSE
7.74
HIGH
7.73
LOW
7.38
VOLUME
71.49K
TURNOVER
--
52 WEEK HIGH
10.14
52 WEEK LOW
4.070
MARKET CAP
531.04M
P/E (TTM)
-19.5813
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ACIU stock price target is 12.59 with a high estimate of 18.08 and a low estimate of 8.18.

EPS

ACIU News

More
AC Immune (ACIU) Presents At UBS Global Healthcare Conference - Slideshow
Seeking Alpha - Article · 05/20 19:51
AC Immune CEO to Showcase Novel Target Programs at UBS Global Healthcare Conference
GlobeNewswire · 05/15 12:00
AC Immune SA (NASDAQ:ACIU) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Simply Wall St. · 05/06 15:12
AC Immune EPS beats by CHF0.05, beats on revenue
AC Immune (NASDAQ:ACIU): Q1 Non-GAAP EPS of -CHF0.09 beats by CHF0.05; GAAP EPS of -CHF0.11 beats by CHF0.03. Revenue of CHF12.41M (-83.5% Y/Y) beats by CH
seekingalpha · 05/04 16:29
AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates
Zacks · 05/04 13:35
AC Immune Reports Q1 2020 Financial Results and Provides Business Update
GlobeNewswire · 05/04 12:00
AC Immune Q1 EPS $(0.110) Down From $0.840 YoY, Sales $12.870M Down From $74.292M YoY
AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.110) per share. This is a 113.1 percent decrease over earnings of $0.840 per share from the same period last year. The company reported $12.870 million in sales
Benzinga · 05/04 11:10
Axsome Shares Jump 25% on Alzheimer's Study Results
GuruFocus.com · 04/28 16:16

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About ACIU

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
More

Webull offers kinds of AC Immune SA stock information, including NASDAQ:ACIU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACIU stock news, and many more online research tools to help you make informed decisions.